Five Prime names Robert Sikorski as chief medical officer
Prior to being appointed Chief Medical Officer, Dr. Sikorski was most recently Senior Vice President, Global Clinical Development, at Five Prime.
Prior to joining Five Prime as Vice President of Global Clinical Development in 2014, Dr. Sikorski was Senior Director, Global Oncology Research and Development at MedImmune (the Biologics Division of AstraZeneca, PLC), where he and his team led the clinical development of a portfolio of immuno-oncology drugs.
He also played a leading role in building this portfolio through partnering and acquisition efforts, that included OX40 (MEDI0562, MEDI06469, and MEDI06383), PD1 (AMP-514), CTLA4 (tremelimumab), an oncolytic virus, and TLR targeting assets.
Prior to Medimmune, he served as Director, Global Oncology Research and Development at Amgen, where he led late stage clinical development and post marketing efforts for several oncology drug candidates.
His seminal work on panitumumab (now marketed as Vectibix) led to the drug's approval with a first-in-class companion diagnostic based on KRAS genotype.
Dr. Sikorski began his career as a Howard Hughes Research Fellow and Visiting Scientist at the National Cancer Institute and the National Human Genome Research Institute in the laboratory of Nobel Laureate Harold Varmus.
Dr. Sikorski received an M.D. and Ph.D. from The Johns Hopkins University School of Medicine through a Medical Scientist Training Program scholarship.
He completed his residency at Massachusetts General Hospital and an oncology fellowship at The Johns Hopkins Oncology Center, and is board certified in both medical oncology and internal medicine.